Andreessen Horowitz, General Catalyst AND Khosla’s ventures were the most active U.S. investors to guide Series A and B funding rounds globally in the first half of 2024. The three topped the list of 13 investors to make seven or more early-stage investments.
We found that almost all of the more active investors listed above increased their investment pace in comparison with a yr earlier, which can indicate that enterprise capital markets could also be starting to achieve momentum.
Of the three most active investors, Khosla Ventures accelerated more dynamically in comparison with H1 2023, leading the Series B rounds in hydrogen services in geology pigeonautonomous truck driving service Guarantee (co-hosted with Uber) and a startup that automates radiology report writing AI Council.
Andreessen was one of the leading investors to boost fewer Series A and Series B rounds in comparison with a yr earlier. But Andreessen still tops the leaderboard this yr. The firm has also been one of the more active multi-stage enterprise capital investors since the second half of 2022, when enterprise capital funding slowed, based on an evaluation of Crunchbase data.
LED amounts
If we glance at the amounts invested by the same investors in Series A and B, we are going to notice a large discrepancy. Arch Venture PartnersThe life sciences investor tops the list with $1.9 billion invested in rounds he led or co-led. Arch co-led a $1 billion round of financing from Foresite Capital at an AI drug discovery company Xiara Therapy.
General Catalystwhich led rounds reaching $1 billion in the first half of the yr, co-led a round in Mistral With Global DST. He also led the B series in Collaborative Roboticswhich involves building robots that collaborate with people.
Andreessen co-led the Series B project for AI voice software ElevenLabs with angel investors Nat Friedman AND Daniel GrossThe company was also a Series A leader in text-to-image AI Ideograms.
Healthcare and AI are leading the way
The growth in U.S. Series A and B funding in the first half of 2024 was concentrated in larger bets and two leading industries: healthcare/biotech and artificial intelligence, based on an evaluation of Crunchbase data.
These two industries stood out among the 125 Series A and B investments led by these active firms. AI-related corporations accounted for 40% of the corporations, and healthcare/biotech around 25%. Other notable sectors included financial services corporations with 13% of the investments and hardware with around 11%.
Off peak
When we glance at the most active leads in Series A and B rounds in the first half of 2022, i.e. the peak variety of A and B rounds led by a US investor, we see a completely different picture. Tiger Global He has led or co-led 100 rounds at this stage, while Insight Partners led 75 in the world. Going into H1 2024, Tiger Global led just one round in the first half of 2024, while Insight led six in Series A and B based on rounds disclosed on Crunchbase.
Seed to A
The more dynamic funding environment in comparison with other stages of the crisis has raised questions about startups’ possibilities of moving beyond the seed stage.
The increase in Series A and B financing in the first half of the yr and the faster pace of activities of leading investors indicate higher prospects for the enterprise capital market in the future.
Methodology
The data in this report comes directly from Crunchbase and is based on reported data. Reported data is as of August 14, 2024.
It is vital to keep in mind that data delays are most noticeable in the earliest stages of a project’s operation.
Please note that every one funding values are reported in US dollars unless otherwise noted. Crunchbase converts foreign exchange to US dollars at the prevailing spot rate from the date that funding rounds, acquisitions, IPOs, and other financing events are reported. Even if these events are added to Crunchbase well after the event is announced, foreign currency transactions are converted at the historical spot price.